 AGOURA HILLS, California, March 15, 2021 GLOBE NEWSWIRE -- Mateon Therapeutics Inc. OTCQB:MATN today announced the regulatory approval from the Ministry of Food and Drug Safety of Korea for the phase 1b clinical trial of a patented OT-101IL-2 combination. This phase 1b clinical trial will confirm the safety and effectiveness of OT-101IL-2 in solid cancer patients in cooperation with the UK global pharmaceutical company Clinigen Group. The study will be conducted together with Autotelic BIO- a partner of Mateon on OT-101IL-2 combination. 